Sun Pharma Q3 Results Review — Branded Markets Growth Outpace Expectations; Systematix Retains 'Buy'

Potential new launches of Deuruxolitinib and Nidlegy over next few quarters can help Sun Pharma sustain a double-digit growth in its specialty portfolio, adds the brokerage.